# Anticoagulation

Madeleine Turcotte

---

<table>
<colgroup>
<col style="width: 22%" />
<col style="width: 18%" />
<col style="width: 18%" />
<col style="width: 18%" />
<col style="width: 21%" />
</colgroup>
<thead>
<tr class="header">
<th>Agent</th>
<th>Treatment Dose</th>
<th>Renal Dose</th>
<th>Prophylaxis</th>
<th>Monitoring</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Unfractionated heparin</td>
<td>80 U/kg bolus, then 18 U/kg/hr</td>
<td>No change necessary</td>
<td>5000 U q8h</td>
<td>PTT (automatic in order set)</td>
</tr>
<tr class="even">
<td><p>Enoxaparin</p>
<p>(Lovenox)</p></td>
<td>1 mg/kg q12h</td>
<td>1 mg/kg daily</td>
<td><p>40 mg daily</p>
<p>      or</p>
<p>30 mg BID</p></td>
<td><p>LMWH level (anti-Xa level)</p>
<p>Best checked 4 h after 4th dose</p>
<p> </p></td>
</tr>
<tr class="odd">
<td>Warfarin (Coumadin)</td>
<td><p>Start 2-5mg daily and monitor INR</p>
<p>Can consult Pharmacy</p>
<p> </p></td>
<td><p>No change</p>
<p>necessary</p></td>
<td>N/A</td>
<td><p>PT/INR</p>
<p>Use Chromogenic Factor X assay if pt has APLS</p></td>
</tr>
<tr class="even">
<td>Dabigatran (Pradaxa)</td>
<td><p>After 5 days of a parenteral AC,</p>
<p>150 mg BID</p></td>
<td>Avoid use</td>
<td>N/A</td>
<td><p>Can test drug level if concerned</p>
<p>(Any DOAC)</p></td>
</tr>
<tr class="odd">
<td>Rivaroxaban (Xarelto)</td>
<td>15 mg BID x21 d then 20 mg daily</td>
<td>Avoid use in CrCl&lt;30</td>
<td>10mg QD</td>
<td> </td>
</tr>
<tr class="even">
<td>Apixaban (Eliquis)</td>
<td>10mg BID x7d, then 5mg BID</td>
<td>VTE: No adjustment</td>
<td>2.5 mg BID</td>
<td><p>A Fib:</p>
<p>2.5mg BID, if 2 of the following:</p>
<p>Cr 1.5, Age &gt; 80</p>
<p>Weight &lt; 60kg</p></td>
</tr>
<tr class="odd">
<td>Edoxaban (Savaysa)</td>
<td><p>After 5 days of a parenteral AC,</p>
<p>60 mg daily</p></td>
<td><p>30 mg for</p>
<p>CrCl 15-50</p>
<p>Avoid if CrCl &gt; 95</p></td>
<td> </td>
<td>Best studied option in renal dysfunction</td>
</tr>
</tbody>
</table>

## Additional Information

- VA is starting to move towards rivaroxaban and apixaban for extended
    secondary thromboprophylaxis
    - Write in your PADR for apixaban citing “patient uses a pillbox and
    cannot use dabigatran”
- Renal dysfunction: favor warfarin, apixaban or edoxaban
- Hx of GI bleed: avoid dabigatran, rivaroxaban, edoxaban (may have
    higher risk of GI bleed)
- Pregnancy: UFH/LMWH (other agents may cross the placenta)

## Transitioning Between Anticoagulants with DOACs

- LMWH to Warfarin
    - Warfarin and LMWH given simultaneously until INR is therapeutic for
    24 hours
- Warfarin to DOAC
    - Start DOAC when INR < 2.0
- DOAC to Warfarin
    - High Risk DVT/PE – start LMWH or UFH, then start Warfarin
    - Low to Moderate Risk DVT/PE – Start warfarin while patient on DOAC,
    Stop DOAC on Day 3 of warfarin therapy, Check INR on day 4
- LMWH to DOAC
    - Stop LMWH and start DOAC when due for next dose of LMWH (within 2
    hrs)
- DOAC to LMWH
    - Stop DOAC and start LMWH when due for next DOAC dose
- UFH to DOAC
    - Start DOAC when IV stopped (30 min prior to cessation if high risk
    for thrombosis)
- DOAC to UFH
    - Start IV heparin with bolus when next DOAC dose is due

## Peri-Procedural Management of Anticoagulation

- Temporary IVC filter indicated in pts with very recent acute VTE
    (within 3-4 weeks) if the procedure requires AC delay >12 hours
- For those at high risk of thromboembolism:
    - Consider continuing AC for low-bleeding-risk procedures, i.e. dental
        procedures, cutaneous biopsy/excision, ICD placement, endovascular
        procedures.
    - Can bridge with LMWH or heparin drip

<table>
<colgroup>
<col style="width: 22%" />
<col style="width: 43%" />
<col style="width: 33%" />
</colgroup>
<thead>
<tr class="header">
<th></th>
<th>Stop before procedure</th>
<th>Restart after procedure</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Warfarin</td>
<td>5 days prior, check INR day of</td>
<td>12 to 24 hours after</td>
</tr>
<tr class="even">
<td>Dabigatran</td>
<td rowspan="4"><p>48 hours prior</p>
<p>(longer if CrCl 30-50 or procedure is high bleeding risk)</p></td>
<td rowspan="4"><p>1 day after</p>
<p>(2 days if high bleeding risk)</p></td>
</tr>
<tr class="odd">
<td>Rivaroxaban</td>
</tr>
<tr class="even">
<td>Apixaban</td>
</tr>
<tr class="odd">
<td>Edoxaban</td>
</tr>
<tr class="even">
<td>Heparin</td>
<td>Stop infusion 4-5 hours prior</td>
<td>24 hours after</td>
</tr>
<tr class="odd">
<td>Enoxaparin</td>
<td>12 - 24 hours prior</td>
<td>24 hours after, (48-72 hours if high bleeding risk)</td>
</tr>
</tbody>
</table>

## Strategies for Reversal of Anticoagulation

### Warfarin

- Vitamin K: onset within a few hours but takes 24-48 hrs for full
    effect
- Life Threatening Bleeding: Give IV Vitamin K 10 mg over 30 minutes
- Intracranial bleed, bleed with hemodynamic instability, emergent
    procedure non-life threatening
    - INR <5: Vitamin K not recommended
    - INR 5-10: Vitamin K 1-5 mg IV or PO
    - INR >10: Vitamin K 5mg PO or 5 mg IV
- Prior to surgery
    - Rapid reversal INR > 5: 5mg Vit K IV (24 hours prior to
        procedure)
- FFP
    - 15 ml/kg (i.e. 4 units/70 kg person) if need reversal <24 hrs, plus
        give Vitamin K
- KCentra ($$$): Contains Factors II, VII, IX, and X with Protein C,
    Protein S, and heparin
    - Given instead of plasma when insufficient time for plasma/Vit K to
        work (i.e. for life threatening hemorrhage)
    - Avoid giving this in HIT
    - Administer with Vitamin K

### Dabigatran

- Idarucizumab ($$$) will reverse if prolonged thrombin time (remember
    to check!) – Consult Hematology

### Factor Xa Inhibitors (rivaroxaban, apixaban, edoxaban)

- FEIBA (Factor VIII inhibitor bypassing activity) – can promote
    coagulation but is <u>not a reversal agent</u>; limited data to
    support use
- Consult Hematology before using; andexanet alfa (FDA approved) is
    not on VUMC formulary but is on the VA formulary
